Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2024-03-28 Board/Management Inform…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
J.Dauenhauer_zgoda
Board/Management Information Classification · 98% confidence The document is a formal declaration ('Oświadczenie') in Polish where an individual consents to be nominated and serve as a member of the Supervisory Board ('Rady Nadzorczej') of PHARMENA S.A. It includes specific declarations regarding independence criteria, legal standing, and conflicts of interest, which are standard requirements for board members. This type of document directly relates to the composition and governance structure of the company's board. Among the provided codes, 'Board/Management Information' (MANG) is the most appropriate fit, as it covers announcements of changes in the board of directors or senior management, and this document confirms a new board member's acceptance of the role. It is not an AGM presentation, an earnings release, or a general regulatory filing.
2024-03-28 Polish
Informacja dot Jacka Dauenhauera
Board/Management Information Classification · 98% confidence The document text is in Polish and details information about Mr. Jacek Dauenhauer, specifically his appointment as a member of the Supervisory Board ('Członek Rady Nadzorczej') on June 13, 2023. It provides extensive background on his professional history, qualifications, and other board/management roles he holds in various entities. This type of disclosure, focusing on the appointment, qualifications, and potential conflicts of interest for a member of the supervisory or management body, strongly aligns with the definition of Board/Management Information (MANG). It is not an annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-03-28 Polish
A.Dziki_zgoda
Board/Management Information Classification · 98% confidence The document is a formal declaration ('Oświadczenie') by an individual, Agnieszka Dziki, consenting to be nominated and serve as a member of the Supervisory Board ('Rada Nadzorcza') of PHARMENA S.A. It details compliance with various legal criteria regarding independence, lack of conflicts of interest, and legal standing required for board members in Poland. This type of document directly relates to the composition and governance structure of the company's board, fitting the definition of Board/Management Information (MANG). It is not an earnings release, annual report, or a general regulatory filing.
2024-03-28 Polish
Informacja dot Agnieszki Dziki
Board/Management Information Classification · 95% confidence The document provides detailed information regarding a specific individual, Agnieszka Dziki, who is a member of the Supervisory Board ('Członek Rady Nadzorczej'). It lists her appointment date, qualifications, professional history, and other business activities, explicitly referencing Polish regulations concerning information disclosed by issuers of securities ('Rozporządzenia Ministra Finansów z dnia 29 marca 2018 roku'). This structure—detailing the background and potential conflicts of interest for a board member—is characteristic of disclosures related to corporate governance or management changes. Since it details the background of a board member rather than announcing a change (which would be MANG), and it focuses heavily on the structure and roles within the company's oversight body, it aligns best with Board/Management Information (MANG) or Governance Information (CGR). Given the focus on the individual's qualifications and role as a Supervisory Board member, MANG (Board/Management Information) is the most precise fit for reporting on the status/details of a key manager/director.
2024-03-28 Polish
Kandydaci do Rady Nadzorczej - Content (PL)
Governance Information Classification · 95% confidence The document text, written in Polish, discusses the nomination of candidates for the Supervisory Board (Rada Nadzorcza) ahead of an Annual General Meeting (Zwyczajnym Walnym Zgromadzeniem Spółki) scheduled for April 3, 2024. This content directly relates to the composition of the board and governance structure being presented to shareholders for approval at the AGM. While it involves board members, the context is the nomination process for the AGM, which is closely related to governance and AGM materials. Given the options, this announcement about candidates for the Supervisory Board, which is a key governance body, fits best under Governance Information (CGR) or potentially AGM-R. Since it details the proposed structure/members of the board being put to a vote, CGR (Governance Information) is a strong fit, as it covers board structure and practices. However, since the context is explicitly tied to the upcoming AGM and the nomination of candidates for the board, it also strongly relates to AGM materials. Given the specific focus on board composition nominations, CGR is the most precise fit for governance structure updates, although AGM-R is also plausible. I will select CGR as it focuses on the structure/members of the board being proposed. The document is short and appears to be a regulatory disclosure (Raport Bieżący) announcing the candidates and stating that their CVs are attached.
2024-03-28 Polish
Sprawozdanie RN o wynagrodzeniach 2023
Remuneration Information Classification · 98% confidence The document title is "Sprawozdanie Rady Nadzorczej o wynagrodzeniach za rok obrotowy 2023" (Report of the Supervisory Board on remuneration for the financial year 2023). The text explicitly discusses remuneration policies, total compensation for management board members and supervisory board members, and references Polish legal articles (Art. 90g of the Public Offering Act) related to remuneration reporting. This content directly aligns with the definition of a report detailing compensation for top executives and directors, which corresponds to the 'Remuneration Information' category. Although the document is a full report (length > 30k chars), the specific subject matter points strongly to the remuneration disclosure requirement, which is mapped to the 'DEF 14A' code in the provided schema, despite DEF 14A typically being a US SEC filing (Proxy Statement/Information Statement related to executive compensation). Given the provided definitions, 'DEF 14A' is the closest match for a detailed remuneration report, as 'AR' (Audit Report) or 'ER' (Earnings Release) are incorrect, and there is no specific 'Remuneration Report' code other than DEF 14A which is often used broadly for compensation disclosures in some classification systems, or 'RPA'/'RNS' which are for announcements, not the report itself. Since this is the actual report content, DEF 14A is the most appropriate classification based on the content focus on executive compensation.
2024-03-05 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.